Wells Fargo & Company MN lessened its stake in shares of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) by 48.9% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 37,704 shares of the biopharmaceutical company’s stock after selling 36,061 shares during the period. Wells Fargo & Company MN owned approximately 0.07% of Tetraphase Pharmaceuticals worth $268,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently modified their holdings of the company. UBS Group AG lifted its position in Tetraphase Pharmaceuticals by 2.3% during the first quarter. UBS Group AG now owns 17,269 shares of the biopharmaceutical company’s stock valued at $159,000 after purchasing an additional 387 shares in the last quarter. State of Wisconsin Investment Board purchased a new position in shares of Tetraphase Pharmaceuticals in the second quarter valued at about $200,000. American International Group Inc. lifted its position in shares of Tetraphase Pharmaceuticals by 7.1% in the first quarter. American International Group Inc. now owns 22,390 shares of the biopharmaceutical company’s stock valued at $206,000 after acquiring an additional 1,486 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of Tetraphase Pharmaceuticals by 88.2% in the first quarter. JPMorgan Chase & Co. now owns 23,115 shares of the biopharmaceutical company’s stock valued at $212,000 after acquiring an additional 10,834 shares in the last quarter. Finally, Rhumbline Advisers lifted its position in shares of Tetraphase Pharmaceuticals by 5.7% in the second quarter. Rhumbline Advisers now owns 51,633 shares of the biopharmaceutical company’s stock valued at $368,000 after acquiring an additional 2,780 shares in the last quarter. 58.19% of the stock is owned by institutional investors.
Shares of Tetraphase Pharmaceuticals, Inc. (TTPH) traded down $0.31 on Monday, hitting $6.00. The stock had a trading volume of 707,971 shares, compared to its average volume of 710,869. Tetraphase Pharmaceuticals, Inc. has a 12-month low of $3.57 and a 12-month high of $9.93.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last released its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.63). The firm had revenue of $4.10 million for the quarter, compared to the consensus estimate of $1.59 million. Tetraphase Pharmaceuticals had a negative return on equity of 88.27% and a negative net margin of 1,382.33%. The firm’s revenue was up 355.6% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.58) EPS. sell-side analysts expect that Tetraphase Pharmaceuticals, Inc. will post -2.88 earnings per share for the current year.
In related news, Director L Patrick Gage purchased 3,880 shares of the firm’s stock in a transaction that occurred on Wednesday, November 29th. The shares were purchased at an average cost of $6.45 per share, with a total value of $25,026.00. Following the purchase, the director now owns 38,880 shares of the company’s stock, valued at approximately $250,776. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Jacques Dumas sold 8,750 shares of the firm’s stock in a transaction dated Tuesday, October 31st. The shares were sold at an average price of $6.03, for a total transaction of $52,762.50. Following the completion of the transaction, the insider now directly owns 8,750 shares in the company, valued at $52,762.50. The disclosure for this sale can be found here. 5.50% of the stock is currently owned by company insiders.
Several brokerages have recently issued reports on TTPH. ValuEngine cut Tetraphase Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday. HC Wainwright boosted their price objective on Tetraphase Pharmaceuticals from $15.00 to $17.00 and gave the stock a “buy” rating in a research note on Monday, November 6th. Zacks Investment Research cut Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, November 4th. BMO Capital Markets upped their target price on Tetraphase Pharmaceuticals from $13.00 to $24.00 and gave the company an “outperform” rating in a research note on Wednesday, October 4th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Tetraphase Pharmaceuticals in a report on Sunday, September 17th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. Tetraphase Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $15.15.
COPYRIGHT VIOLATION NOTICE: “Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Stake Lessened by Wells Fargo & Company MN” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another publication, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2017/12/04/tetraphase-pharmaceuticals-inc-ttph-shares-sold-by-wells-fargo-company-mn.html.
Tetraphase Pharmaceuticals Company Profile
Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.
Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.